Latest Options Exercise News

Xanadu Mines has transitioned operatorship of its flagship Kharmagtai project to Zijin Mining, delivered key feasibility milestones, and is now exploring strategic funding and corporate options amid a solid cash position.

Rapid Lithium Ltd completed a $2 million entitlement capital raising and progressed key US and Canadian projects targeting lithium and strategic metals amid shifting global supply dynamics.

Flynn Gold Limited reported significant progress in its Tasmanian projects during the March 2025 quarter, highlighted by ongoing diamond drilling at Golden Ridge and discovery of new high-grade gold and silver-lead-zinc targets. The company secured $2.6 million in fresh capital to fund accelerated exploration.

Island Pharmaceuticals has completed dosing in the Phase 2b cohort of its dengue fever trial, with pharmacokinetic targets met and top-line results expected next month. The company also strengthened its balance sheet by raising $1.94 million through option exercises.

Pancontinental Energy reports a significant 3.8 billion barrels of net prospective oil resources at its Saturn Complex in Namibia’s PEL 87, advancing farmout talks and environmental approvals for exploration drilling.

Forrestania Resources delivered strong high-grade gold drilling results at Ada Ann and Lady Lila, while exercising key options to broaden its exploration footprint in Western Australia.

Brazilian Critical Minerals Ltd reports a significant resource upgrade and strong scoping study results for its Ema rare earth project in Brazil, highlighting low operating costs and promising economics.

Caprice Resources has reported strong drilling results at its Island Gold Project, including a new high-grade gold discovery south of Vadrians Hill, and has commenced an extensive Phase 3 drilling program to expand its maiden resource potential.

Panther Metals reports strong high-grade gold intercepts at its Laverton Gold Project, particularly at Burtville East, alongside a $685,000 capital raise to fund further exploration.

Peako Limited reports a quiet quarter in East Kimberley exploration due to seasonal conditions but successfully completes a significant capital raise, bolstering its cash position to nearly A$2 million.

Core Energy Minerals has expanded its uranium portfolio with key South Australian acquisitions and secured $3.7 million in funding, setting the stage for maiden drilling at the Cummins Project.

Paradigm Biopharmaceuticals has secured ethics approval and appointed a CRO to launch its global phase 3 trial for injectable Pentosan Polysulfate Sodium in knee osteoarthritis, while initiating a substantial capital raising program.